Insider · CIK 0001727393
Andrew Paul Mazar
Files at MNPR (Monopar Therapeutics), ACTU (ACTUATE THERAPEUTICS, INC.). First filing -, latest -.
Andrew Paul Mazar files SEC Form 4 as COO at MNPR (Monopar Therapeutics), and also at ACTU (ACTUATE THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Andrew Paul Mazar has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | ACTU ACTUATE THERAPEUTICS, INC. | AGrant or award Employee Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Apr 1, 2026 |
| Apr 1, 2025 | ACTU ACTUATE THERAPEUTICS, INC. | AGrant or award Employee Stock Option (right to buy)derivative | +51,046 | $0.00 | $0 | 51,046 | Apr 2, 2025 |
| Apr 1, 2025 | ACTU ACTUATE THERAPEUTICS, INC. | AGrant or award Employee Stock Option (right to buy)derivative | +110,346 | $0.00 | $0 | 110,346 | Apr 2, 2025 |
Questions about Andrew Paul Mazar
Answered from the filings on this page, as of the latest one.
Is Andrew Paul Mazar buying or selling?
Andrew Paul Mazar has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Andrew Paul Mazar's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew Paul Mazar has 0.
Where does Andrew Paul Mazar file Form 4?
Andrew Paul Mazar has filed Form 4 at MNPR (Monopar Therapeutics); ACTU (ACTUATE THERAPEUTICS, INC.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.